Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Rare Diseases

Most Promising Applications of Artificial Intel...

Artificial Intelligence (AI), with its wide range of applications, is enhancing the speed and accuracy of businesses across various industries such as manufacturing, healthcare, finance, marketing,...

Feb 09, 2022

pharma-news-for-biogen-sanofi-bristol-pharming-ucb-eli-lilly
Biogen’s Aduhelm; FDA Approves Sanofi’s Enjaymo; NHS & Orchard Signs a Deal; Bristol’s Breyanzi & Abecma; Pharming’s Leniolisib; Eli Lilly’s Verzenio Trial; UCB’ Zilucoplan Trials Result; Eli Lilly’s Alzheimer’s Drug Donanemab

Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair...

Find More
pharma-news-for-merck-pfizer-gilead-abbvie-lantern-polpharma
Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Find More
nerve-monitoring-market
The Evolving Neurofibromatosis Treatment Landscape

Neurofibromatosis is a progressive and autosomal dominant inherited disorder of the nervous system which causes tumors to form on the nerves anywhere in the body, at any time. Neurofibromatosis skin lesions are typically flat, pigmented patches but occasionally are elevated flesh-colored bumps. There are three d...

Find More

More Views & Analysis

medtech-news-for-boston-scientific-bd-roche-linus-helioliver
Boston Scientific’s MODULAR CRM System; Restore Medical’s ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus’s StrandDx-ASD; HelioLiver launches liquid biopsy test

Boston Scientific initiates trial to evaluate industry's first Modular CRM System  On December 02, 2021, Boston Scientific Corporation started the MODULAR ATP clinical trial to examine the safety, performance, and effectiveness of the mCRM™ Modular Therapy System. The system comprises of two cardiac ...

Find More

pharma-news-for-aslan-iqvia-reata-recordati-eusa
Aslan Pharma – IQVIA collaboration; Reata’s kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA

Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA   ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organisation for log...

Find More

pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given priority review for Zynteglo, its gene therapy for the rare blood disorder beta-thalassemia. The announcement sets up an expe...

Find More

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Patients with more severe forms of the disease can experience s...

Find More

Fda-Approved-Top-Drugs-Launched-in-2021
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1)

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceutical sector at every stage of the process. CDER offers scientific and regulatory assistance needed to bring innovative m...

Find More

von-willebrand-disease-vwd-market
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is one of these proteins (VWF). VWD patients have either a low level of VWF in their blood or the VWF protein does not functi...

Find More

Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....

Find More

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that results in systemic inflamma.....

Find More

Thyroid Eye Disease (TED), also known as Grave’s Ophthalmopathy, is an autoimmune disorder in whic.....

Find More

Tinnitus is a condition where a person experiences different kinds of noises in one or both ears. It.....

Find More

Celiac disease is an autoimmune disorder against the gluten consumed that creates toxins, thereby, d.....

Find More

Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukem.....

Find More